Version history

{
  "session_id": "sess_AD-MASTER-PLAN-APOE-20260428030754_task_66f1207e_ctx",
  "round_number": 4,
  "agent_persona": "persona-synthesizer",
  "agent_backend": "scidex.core.llm.complete",
  "action": "synthesize",
  "content": "{\n  \"ranked_hypotheses\": [\n    {\n      \"title\": \"APOE4 lipid dysregulation and synaptic phagocytosis as early drivers of AD pathology requires proximal validation\",\n      \"description\": \"The debate supports carrying forward APOE4 lipid dysregulation and synaptic phagocytosis as early drivers of AD pathology only if a proximal endpoint changes before the late outcome. The decisive validation path is: compare APOE4-to-APOE3 correction in neuron-microglia-astrocyte co-cultures with amyloid, lipid, and synapse engulfment readouts.\",\n      \"target_gene\": \"APOE\",\n      \"dimension_scores\": {\n        \"evidence_strength\": 0.57,\n        \"novelty\": 0.64,\n        \"feasibility\": 0.69,\n        \"therapeutic_potential\": 0.58,\n        \"mechanistic_plausibility\": 0.67,\n        \"druggability\": 0.5,\n        \"safety_profile\": 0.55,\n        \"competitive_landscape\": 0.55,\n        \"data_availability\": 0.63,\n        \"reproducibility\": 0.66\n      },\n      \"composite_score\": 0.604,\n      \"evidence_for\": [\n        {\n          \"claim\": \"Preregistered claim: APOE4-driven lipid dysregulation and synaptic phagocytosis drive AD; converting APOE4 to APOE3 reduces amyloid and restores synaptic function\",\n          \"source\": \"AD-MASTER-PLAN-APOE-20260428030754\"\n        }\n      ],\n      \"evidence_against\": [\n        {\n          \"claim\": \"APOE genotype affects many cell types, so target conversion could rescue biomarkers without proving synaptic causality\",\n          \"source\": \"AD-MASTER-PLAN-APOE-20260428030754\"\n        }\n      ]\n    },\n    {\n      \"title\": \"Stratified falsifiers should govern AD Master Plan preregistration: APOE\",\n      \"description\": \"Claims from this analysis should be evaluated across APOE, AD, tau, amyloid; pooled effects are insufficient when causal direction, cell state, genotype, benchmark leakage, or reproducibility risks can dominate the result.\",\n      \"target_gene\": \"AD\",\n      \"dimension_scores\": {\n        \"evidence_strength\": 0.54,\n        \"novelty\": 0.59,\n        \"feasibility\": 0.74,\n        \"therapeutic_potential\": 0.5,\n        \"mechanistic_plausibility\": 0.61,\n        \"druggability\": 0.43,\n        \"safety_profile\": 0.59,\n        \"competitive_landscape\": 0.53,\n        \"data_availability\": 0.68,\n        \"reproducibility\": 0.7\n      },\n      \"composite_score\": 0.591,\n      \"evidence_for\": [\n        {\n          \"claim\": \"The analysis question names specific entities or evaluation structure.\",\n          \"source\": \"AD-MASTER-PLAN-APOE-20260428030754\"\n        }\n      ],\n      \"evidence_against\": [\n        {\n          \"claim\": \"The current record can still be confounded by stage, leakage, or artifact effects.\",\n          \"source\": \"AD-MASTER-PLAN-APOE-20260428030754\"\n        }\n      ]\n    },\n    {\n      \"title\": \"APOE should remain under review until replicated\",\n      \"description\": \"The consensus is to preserve this as a debated candidate, not a canonical world-model claim. Replication or rerun evidence should precede promotion into Atlas or market funding.\",\n      \"target_gene\": \"tau\",\n      \"dimension_scores\": {\n        \"evidence_strength\": 0.52,\n        \"novelty\": 0.55,\n        \"feasibility\": 0.71,\n        \"therapeutic_potential\": 0.52,\n        \"mechanistic_plausibility\": 0.58,\n        \"druggability\": 0.45,\n        \"safety_profile\": 0.58,\n        \"competitive_landscape\": 0.52,\n        \"data_availability\": 0.65,\n        \"reproducibility\": 0.69\n      },\n      \"composite_score\": 0.577,\n      \"evidence_for\": [\n        {\n          \"claim\": \"Concrete next test: compare APOE4-to-APOE3 correction in neuron-microglia-astrocyte co-cultures with amyloid, lipid, and synapse engulfment readouts\",\n          \"source\": \"AD-MASTER-PLAN-APOE-20260428030754\"\n        }\n      ],\n      \"evidence_against\": [\n        {\n          \"claim\": \"Promotion before replication would weaken quality control.\",\n          \"source\": \"AD-MASTER-PLAN-APOE-20260428030754\"\n        }\n      ]\n    }\n  ],\n  \"knowledge_edges\": [\n    {\n      \"source_id\": \"AD-MASTER-PLAN-APOE-20260428030754\",\n      \"source_type\": \"analysis\",\n      \"target_id\": \"APOE\",\n      \"target_type\": \"entity\",\n      \"relation\": \"debate_context_supports_review_of\"\n    },\n    {\n      \"source_id\": \"AD-MASTER-PLAN-APOE-20260428030754\",\n      \"source_type\": \"analysis\",\n      \"target_id\": \"AD\",\n      \"target_type\": \"entity\",\n      \"relation\": \"debate_context_supports_review_of\"\n    },\n    {\n      \"source_id\": \"AD-MASTER-PLAN-APOE-20260428030754\",\n      \"source_type\": \"analysis\",\n      \"target_id\": \"tau\",\n      \"target_type\": \"entity\",\n      \"relation\": \"debate_context_supports_review_of\"\n    },\n    {\n      \"source_id\": \"AD-MASTER-PLAN-APOE-20260428030754\",\n      \"source_type\": \"analysis\",\n      \"target_id\": \"amyloid\",\n      \"target_type\": \"entity\",\n      \"relation\": \"debate_context_supports_review_of\"\n    }\n  ],\n  \"synthesis_summary\": \"Consensus: AD Master Plan preregistration: APOE is substantive enough for debate because it names APOE4 lipid dysregulation and synaptic phagocytosis as early drivers of AD pathology and can be tied to a concrete validation path: compare APOE4-to-APOE3 correction in neuron-microglia-astrocyte co-cultures with amyloid, lipid, and synapse engulfment readouts. Dissent: APOE genotype affects many cell types, so target conversion could rescue biomarkers without proving synaptic causality. The claim should remain under review until the falsifier or replication path is executed.\"\n}",
  "tokens_used": "1354",
  "persona_id": "persona-synthesizer"
}